Xenetic Biosciences, Inc.
XBIO·NasdaqCM·Healthcare
2.0100−0.0700 (−3.37%)today
At close: Nov 4, 4:00 PM EST · May be delayed up to 15 min · USD
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Previous close2.0800
Open2.1200
Day range2.01002.1639
52-week range1.58004.9390
Off day high−7.11%
Off 52-week high−59.30%
Volume10.81K
Avg. volume (3M)88.00K
Market cap4.71M
EPS (TTM)-1.15
Forward P/E-3.05
P/E ratio (TTM)—
Dividend yield—
Beta (5Y)2.35
Shares outstanding2.34M
Short interest0.49% of float
Earnings dateAug 11, 2025 (est.)
Analyst target—
Profit margin−75.91%
Against its peers
Compare in full ›| XBIO | XRTX | PMCB | BDRX | XBIT | TOVX | |
|---|---|---|---|---|---|---|
| Market cap | 4.71M | 1.80M | 4.09M | 1.41M | 59.45M | 8.72M |
| P/E (TTM) | — | — | — | 0.0 | — | 0.3 |
| Forward P/E | -3.0 | 1.2 | -1.0 | — | 15.0 | -1.0 |
| Price/book | 0.8 | 0.3 | 0.1 | 0.0 | 0.5 | 0.7 |
| Dividend yield | — | — | — | — | — | — |
| 1-year change | −24.91% | −65.92% | −61.58% | −98.73% | −18.41% | −40.00% |
| Today | −3.37% | −1.00% | +12.03% | −4.61% | −2.01% | +4.40% |
The closest companies by business and industry (Biotechnology). Prices may be delayed up to 15 min.
Latest news
All XBIO news ›Xenetic Biosciences and PeriNess Announce First Patient Dosed in Investigator-Initiated Study at Tel Aviv Sourasky University Medical Center Evaluating Systemic DNase in Combination with CAR T Cells for Large B-Cell Lymphoma
Eagle-Tribune First clinical evaluation of Xenetic's systemic DNase technol
From the 4Search news index, newest first.
In the news
1mentions in 30 days
1with it in the headline
Positivesentiment
Mentioned with
People in the coverage
Themes
Most coverage from
- defenseworld.net1
Finance and business coverage in the 4SEARCH.business news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 1 articles, not a forecast.